EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access

Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study

Pau Montesinos iD, Rebeca Rodríguez-Veiga, Juan Miguel Bergua iD, Jesús Lorenzo Algarra Algarra iD, Carmen Botella, Eduardo Rodríguez-Arbolí, Teresa Bernal iD, Mar Tormo iD, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega und 40 weitere

Journal of Clinical Oncology · 2026-01 · 44 (1) · 42-53

DOI: 10.1200/jco-25-01841 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2026-01. Verfasst von Pau Montesinos und 51 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitari I Politécnic La Fe, Valencia, Spain. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Phenylurea Compounds, Leukemia, Myeloid, Acute, Benzothiazoles. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Quizartinib, an oral, selective, second-generation, type-II FMS-like tyrosine kinase 3 (FLT3) inhibitor with high binding affinity to internal tandem duplication (ITD) and wild-type (WT) FLT3, has shown early clinical activity as monotherapy in patients with relapsed/refractory FLT3 -ITD–negative AML. The phase III QuANTUM-First trial showed that quizartinib significantly prolonged survival versus placebo when added to standard chemotherapy, followed by single-agent maintenance, in patients with newly diagnosed (ND) FLT3- ITD–positive AML. We investigated the safety and efficacy of quizartinib in patients with ND FLT3 -ITD–negative AML. METHODS The phase II, randomized, double-blind, placebo-controlled QUIWI trial enrolled patients age 18-70 years with ND FLT3 -ITD–negative (mutant-to-WT allelic ratio

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3Phenylurea CompoundsLeukemia, Myeloid, AcuteBenzothiazolesProtein Kinase InhibitorsHumansDouble-Blind MethodMiddle AgedFemaleMaleAdultAgedYoung AdultAdolescentTandem Repeat Sequences

Substanzen

fms-Like Tyrosine Kinase 3quizartinibPhenylurea CompoundsBenzothiazolesFLT3 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Hospital Universitari I Politécnic La Fe, Valencia, Spain.
  • Hospital San Pedro de Alcántara, Cáceres, Spain.
  • Hospital General de Albacete, Albacete, Spain.
  • Hospital General Universitario de Alicante, Alicante, Spain.
  • Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain.
  • Instituto de Investigación Sanitaria del Principado de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Hospital Universitario Central de Asturias, Oviedo, Spain.

ORCID-Profile: Pau Montesinos, Juan Miguel Bergua, Jesús Lorenzo Algarra Algarra, Teresa Bernal, Mar Tormo, Jose Luis López-Lorenzo, Mercedes Colorado, Maria Teresa Olave, Manuel Barrios, Maria Jose Sayas, Marta Polo, Maria Isabel Gómez-Roncero, Eva Barragán, Carmen Chillón, Maria José Calasanz, Bruno Paiva, José Ángel Raposo-Puglia, M Carmen Mateos, Natalia Alonso, David Martínez-Cuadrón

Zitieren

APA

Montesinos, P., Rodríguez-Veiga, R., Bergua, J. M., Algarra Algarra, J. L., Botella, C., Rodríguez-Arbolí, E., Bernal, T., Tormo, M., Calbacho, M., Salamero, O., Serrano, J., Noriega, V., López-López, J. A., Vives, S., López-Lorenzo, J. L., Colorado, M., Vidriales, M. B., García Boyero, R., Olave, M. T., …, & PETHEMA Group (2026). Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study. Journal of Clinical Oncology, 44(1), 42-53. https://doi.org/10.1200/jco-25-01841

Vancouver

Montesinos P, Rodríguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodríguez-Arbolí E, et al. Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study. Journal of Clinical Oncology. 2026;44(1):42-53. doi:10.1200/jco-25-01841

BibTeX
@article{Montesinos2026,
  author = {Montesinos, Pau and Rodríguez-Veiga, Rebeca and Bergua, Juan Miguel and Algarra Algarra, Jesús Lorenzo and Botella, Carmen and Rodríguez-Arbolí, Eduardo and Bernal, Teresa and Tormo, Mar and Calbacho, Maria and Salamero, Olga and Serrano, Josefina and Noriega, Victor and López-López, Juan Antonio and Vives, Susana and López-Lorenzo, Jose Luis and Colorado, Mercedes and Vidriales, Maria-Belén and García Boyero, Raimundo and Olave, Maria Teresa and Herrera Puente, Pilar and Arce, Olga and Barrios, Manuel and Jose Sayas, Maria and Polo, Marta and Gómez-Roncero, Maria Isabel and Barragán, Eva and Ayala, Rosa and Chillón, Carmen and Calasanz, Maria José and Paiva, Bruno and Boluda, Blanca and Casas-Avilés, Ignacio and Lloret-Madrid, Pilar and Sánchez, Maria-José and Rodríguez-Medina, Carlos and Cuevas, Laida and Raposo-Puglia, José Ángel and Mateos, M Carmen and Olivares, Matxalen and Martínez-Chamorro, Carmen and Alonso, Natalia and Suárez, Sandra and Sánchez-Vadillo, Irene and Solé Rodríguez, María and González, Bernardo Javier and Martínez-Francés, Antonio and Cuello, Rebeca and Fernández, Alfonso and Martínez-Cuadrón, David and Labrador, Jorge and PETHEMA group, PETHEMA group and PETHEMA Group, PETHEMA Group},
  title = {Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {1},
  pages = {42--53},
  doi = {10.1200/jco-25-01841}
}
Kostenlos starten →